[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112013005664B8 - Ácidos nucleicos que se ligam a sdf-1 e uso dos mesmos no tratamento de câncer - Google Patents

Ácidos nucleicos que se ligam a sdf-1 e uso dos mesmos no tratamento de câncer

Info

Publication number
BR112013005664B8
BR112013005664B8 BR112013005664A BR112013005664A BR112013005664B8 BR 112013005664 B8 BR112013005664 B8 BR 112013005664B8 BR 112013005664 A BR112013005664 A BR 112013005664A BR 112013005664 A BR112013005664 A BR 112013005664A BR 112013005664 B8 BR112013005664 B8 BR 112013005664B8
Authority
BR
Brazil
Prior art keywords
treatment
sdf
cancer
disorder
disease
Prior art date
Application number
BR112013005664A
Other languages
English (en)
Other versions
BR112013005664A2 (pt
BR112013005664B1 (pt
Inventor
Purschke Werner
Jarosch Florian
Eulberg Dirk
Klussmann Sven
Buchner Klaus
Maasch Christian
Dinse Nicole
Zboralski Dirk
Original Assignee
Noxxon Pharma Ag
TME Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag, TME Pharma AG filed Critical Noxxon Pharma Ag
Publication of BR112013005664A2 publication Critical patent/BR112013005664A2/pt
Publication of BR112013005664B1 publication Critical patent/BR112013005664B1/pt
Publication of BR112013005664B8 publication Critical patent/BR112013005664B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ÁCIDOS NUCLEICOS QUE SE LIGAM A SDF-1 E USO DOS MESMOS NO TRATAMENTO DE CÂNCER. A presente invenção refere-se a uma molécula de ácido nucleico capaz de se ligar a SDF-1, preferencialmente, capaz de inibir SDF-1, em que a molécula de ácido nucleico é para uso em um método para o tratamento e/ou prevenção de uma doença ou distúrbio, para uso em um método para p tratamento de um indivíduo sofrendo de uma doença ou distúrbio ou em risco de desenvolver uma doença ou distúrbio com uma terapia adjunta, ou para uso como um medicamento para o tratamento e/ou prevenção de uma doença ou distúrbio, sendo que a doença ou distúrbio é câncer.
BR112013005664A 2010-09-09 2011-09-09 Ácidos nucleicos que se ligam a sdf-1 e uso dos mesmos no tratamento de câncer BR112013005664B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10009397 2010-09-09
EP10009397.0 2010-09-09
PCT/EP2011/004554 WO2012031773A1 (en) 2010-09-09 2011-09-09 Sdf-1 binding nucleic acids and the use thereof in cancer treatment

Publications (3)

Publication Number Publication Date
BR112013005664A2 BR112013005664A2 (pt) 2020-08-04
BR112013005664B1 BR112013005664B1 (pt) 2021-11-03
BR112013005664B8 true BR112013005664B8 (pt) 2023-04-25

Family

ID=44653255

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005664A BR112013005664B8 (pt) 2010-09-09 2011-09-09 Ácidos nucleicos que se ligam a sdf-1 e uso dos mesmos no tratamento de câncer

Country Status (15)

Country Link
US (3) US20130310442A1 (pt)
EP (1) EP2613789B1 (pt)
JP (1) JP6243736B2 (pt)
KR (1) KR101937939B1 (pt)
CN (1) CN103108641B (pt)
AU (1) AU2011300818B2 (pt)
BR (1) BR112013005664B8 (pt)
CA (1) CA2810950C (pt)
DK (1) DK2613789T3 (pt)
ES (1) ES2678497T3 (pt)
HK (1) HK1184699A1 (pt)
MX (1) MX357770B (pt)
RU (1) RU2679495C2 (pt)
SG (2) SG188220A1 (pt)
WO (1) WO2012031773A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2613789B1 (en) * 2010-09-09 2018-04-18 Noxxon Pharma AG Sdf-1 binding nucleic acids and the use thereof in cancer treatment
US11371045B2 (en) * 2016-04-15 2022-06-28 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
US20230301950A1 (en) 2020-06-26 2023-09-28 Raqualia Pharma Inc. Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
EP1072273B1 (en) 1998-03-24 2006-07-26 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
NZ507161A (en) * 1998-03-30 2003-12-19 Northwest Biotherapeutics Inc Theraupeutic and diagonistic applications based on the role of the CXCR-4 gene in tumorigenesis
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
CA2412493C (en) * 2000-06-26 2010-11-09 Wellstat Biologics Corporation Purging of cells using viruses
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20060019917A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
KR100635703B1 (ko) 2001-06-07 2006-10-17 케모센트릭스, 인크. 세포 이동성 검사
JP4713082B2 (ja) 2001-10-26 2011-06-29 ノクゾン ファルマ アーゲー 修飾ｌ−核酸
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
WO2004087068A2 (en) * 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
CA2520550A1 (en) 2003-04-13 2004-10-28 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
MXPA06010782A (es) 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
CN101098703B (zh) 2004-11-05 2011-08-03 费城儿童医院 用于分子治疗的生物降解连接剂
EP1883651A1 (en) * 2005-05-26 2008-02-06 Rappaport Family Institute For Research in the Medical Sciences Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions
AU2006280945A1 (en) * 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
KR101561652B1 (ko) * 2006-07-18 2015-10-20 녹손 파르마 아게 Sdf-1 결합형 c형 핵산분자
EP2046834B9 (en) * 2006-08-11 2013-04-10 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
CA2662978A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
US8906680B2 (en) * 2006-12-22 2014-12-09 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
KR101589442B1 (ko) 2007-08-06 2016-02-01 녹손 파르마 아게 에스디에프-1 결합형 핵산 및 이의 용도
EP2613789B1 (en) * 2010-09-09 2018-04-18 Noxxon Pharma AG Sdf-1 binding nucleic acids and the use thereof in cancer treatment

Also Published As

Publication number Publication date
CN103108641B (zh) 2016-01-13
US20130310442A1 (en) 2013-11-21
ES2678497T3 (es) 2018-08-13
SG188220A1 (en) 2013-04-30
MX357770B (es) 2018-07-24
SG10201506725QA (en) 2015-10-29
JP2013540725A (ja) 2013-11-07
EP2613789A1 (en) 2013-07-17
US20160095875A1 (en) 2016-04-07
BR112013005664A2 (pt) 2020-08-04
CN103108641A (zh) 2013-05-15
MX2013002722A (es) 2013-06-28
RU2679495C2 (ru) 2019-02-11
KR101937939B1 (ko) 2019-01-11
RU2013115739A (ru) 2014-10-20
US20160355821A1 (en) 2016-12-08
AU2011300818A1 (en) 2013-03-07
CA2810950A1 (en) 2012-03-15
EP2613789B1 (en) 2018-04-18
AU2011300818B2 (en) 2015-11-12
KR20130114094A (ko) 2013-10-16
DK2613789T3 (en) 2018-07-23
JP6243736B2 (ja) 2017-12-06
CA2810950C (en) 2023-02-14
US9387221B2 (en) 2016-07-12
US10093934B2 (en) 2018-10-09
WO2012031773A1 (en) 2012-03-15
BR112013005664B1 (pt) 2021-11-03
HK1184699A1 (zh) 2014-01-30

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
BR112014002353A2 (pt) métodos de tratamento de câncer usando os antagonistas de ligação do eixo pd-1 e os inibidores de mek
BR112012008282A2 (pt) anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos
BR112012031163A2 (pt) métodos de terapia combinada para tratamento de doenças proliferativas
BR112015008447A2 (pt) métodos para tratar câncer
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
BR112015022998A2 (pt) composições melhoradas para o tratamento de distrofia muscular
AU2011328009A8 (en) Compounds and methods for treating pain
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112016002164A2 (pt) anticorpos de antiactivina a e usos dos mesmos
BR112014023162A8 (pt) compostos e métodos para modulação quinase e indicações dos mesmos
BR112013006673A2 (pt) produtos terapêuticos para câncer de mama
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
BR112015001801A2 (pt) métodos e composições para determinar a resistência à terapia de receptor de androgênio
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/09/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25D Requested change of name of applicant approved

Owner name: TME PHARMA AKTIENGESELLSCHAFT (DE)